SCHEMBL5041392

SCHEMBL5041392

Cc1ccc(S(=O)(=O)O)cc1.Clc1ccc(N2CC3CNCC(C3)C2)cn1

nearest known ligand 0.53

Known targets — ChEMBL curated mechanism

ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
CHRNB2 known ✓ P17787 8/20 0.44
CHRNA4 known ✓ P43681 8/20 0.44
CHRNB4 P30926 8/20 0.45
CHRNA3 P32297 8/20 0.45
CHRNA7 P36544 1/20 0.43
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4827701 0.84 CHRNB4 (0.46) CHRNB4CHRNA3CHRNB2CHRNA4CHRM1
SCHEMBL5038358 0.83 CHRNB2 (0.67) CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7
SCHEMBL5034151 0.82 CHRNB4 (0.64) CHRNB4CHRNA3CHRNB2CHRNA4CHRNA7
SCHEMBL652029 0.80 CHRNB2 (0.71) CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL652028 0.80 CHRNB2 (0.71) CHRNB4CHRNA3CHRNB2CHRNA4
SCHEMBL4823839 0.80 CHRNB2 (0.44) CHRNB4CHRNA3CHRNB2CHRNA4CHRM1
SCHEMBL4825516 0.79 GPR119 (0.43) CHRNB4CHRNA3CHRNB2CHRNA4CHRM1
SCHEMBL4826229 0.78 CHRNB2 (0.41) CHRNB4CHRNA3CHRNB2CHRNA4CHRM1
SCHEMBL4827568 0.78 CHRNB2 (0.41) CHRNB4CHRNA3CHRNB2CHRNA4CHRM1
SCHEMBL4826782 0.78 CHRNB2 (0.41) CHRNB4CHRNA3CHRNB2CHRNA4CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1359152-B1 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands ABBOTT LAB (US) 2008-05-07 EP disclosed
US-7265115-B2 Diazabicyclic CNS active agents ABBOTT LABORATORIES (US) 2007-09-04 US disclosed
US-20030225268-A1 Diazabicyclic CNS active agents ABBVIE INC. 2003-12-04 US disclosed
EP-1359152-A2 Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands ABBOTT LABORATORIES (US) 2003-11-05 EP disclosed
EP-1147112-B1 DIAZABICYCLIC DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ABBOTT LAB (US) 2003-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225268-A1 Diazabicyclic CNS active agents GABRE, GRIN1, CNTN1 CHRNB2 29/4885CHRNA4 14/4885CHRNB4 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.